{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:38:24Z","timestamp":1781876304586,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a fatal immunological syndrome resulting from excessive production of inflammatory cytokines. The conventional therapies for HLH, which are based on cytotoxic agents, are not always efficacious and safe, especially in patients with severe immunodeficiency. Ruxolitinib, a strong inhibitor of Janus kinase (JAK) 1\/2, has already been evaluated as salvage and first-line therapy for HLH. Despite its promising efficacy and tolerability in the treatment of secondary HLH, the efficacy and safety of ruxolitinib in HLH patients with HIV infection remain to be investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Two men (ages: 45 and 58 years) both presented at our hospital with a high fever. They were found to be HIV-positive with severe immunodeficiency and opportunistic infections. Their laboratory tests showed severe pancytopenia, hypofibrinogenemia, hypertriglyceridemia, and increased levels of inflammatory factors and ferritin. Hemophagocytosis was found in the bone marrow, and abdominal computed tomography or ultrasonography showed splenomegaly. Both patients were diagnosed with infection-induced HLH due to severe immunodeficiency. Given they were both highly immunocompromised, we chose ruxolitinib as a first-line treatment alternative to cytotoxic chemotherapy. Rapid remission of clinical symptoms and normalization of laboratory parameters were achieved after ruxolitinib therapy. Neither patient had any associated adverse drug reactions or other laboratory abnormalities. Both patients were eventually discharged and ruxolitinib was discontinued as their disease alleviated, and they did not show signs of relapse during the 3- and 5-month of follow-up examinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We described two cases of AIDS-related secondary HLH treated with ruxolitinib. Our cases highlight the feasibility of using ruxolitinib as a first-line therapy in patients with HIV infection and secondary HLH. Nevertheless, the safety and efficacy of this novel treatment need to be evaluated in large clinical trials in the future.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1012643","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T04:39:12Z","timestamp":1664771952000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dairong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikai","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101515","article-title":"Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy","volume":"34","author":"Griffin","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2007.05.001","article-title":"Hemophagocytic syndromes","volume":"21","author":"Janka","year":"2007","journal-title":"Blood Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24971","article-title":"Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience","volume":"93","author":"Slostad","year":"2018","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2017.07.002","article-title":"Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report","volume":"12","author":"Sin","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005364","article-title":"Ruxolitinib for steroid-resistant acute GVHD","volume":"135","author":"Risitano","year":"2020","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.07.062","article-title":"Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib","volume":"100","author":"Fuchs","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25063","article-title":"Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience","volume":"93","author":"Zandvakili","year":"2018","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4049\/jimmunol.1302282","article-title":"Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis","volume":"192","author":"Johnson","year":"2014","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13837","article-title":"Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years","volume":"172","author":"Schram","year":"2016","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000898","article-title":"Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib","volume":"3","author":"Goldsmith","year":"2019","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.seminhematol.2018.07.006","article-title":"Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH","volume":"57","author":"Wang","year":"2020","journal-title":"Semin Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.710400","article-title":"Ruxolitinib in patients with chronic active Epstein-Barr virus infection: A retrospective, single-center study","volume":"12","author":"Song","year":"2021","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1301","article-title":"Ruxolitinib in alleviating the cytokine storm of hemophagocytic lymphohistiocytosis","volume":"146","author":"Jianguo","year":"2020","journal-title":"Pediatrics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001497","article-title":"Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis","volume":"4","author":"L\u00e9vy","year":"2020","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26091","article-title":"Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis","volume":"96","author":"Boonstra","year":"2021","journal-title":"Am J Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab212","article-title":"Randomized trial of ruxolitinib in antiretroviral-treated adults with human immunodeficiency virus","volume":"74","author":"Marconi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02496-13","article-title":"Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro","volume":"58","author":"Gavegnano","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006740","article-title":"Novel mechanisms to inhibit HIV reservoir seeding using jak inhibitors","volume":"13","author":"Gavegnano","year":"2017","journal-title":"PloS Pathog"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.253781","article-title":"A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis","volume":"106","author":"Zhang","year":"2021","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02882-1","article-title":"Ruxolitinib as first-line therapy in secondary hemophagocytic lymphohistiocytosis and HIV infection","volume":"112","author":"G\u00e1lvez Acosta","year":"2020","journal-title":"Int J Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1012643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T04:39:16Z","timestamp":1664771956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1012643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2022.1012643"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1012643","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"article-number":"1012643"}}